C-reactive protein (CRP) as a biomarker of pulmonary exacerbation presentation and treatment response
VanDevanter, DR, Heltshe, SL, Skalland, M, West, NE, Sanders, DB, Goss, CH, Flume, PA
Published in Journal of cystic fibrosis (01.07.2022)
Published in Journal of cystic fibrosis (01.07.2022)
Get full text
Journal Article
Association of site of treatment with clinical outcomes following intravenous antimicrobial treatment of a pulmonary exacerbation
Sanders, D.B., Khan, U., Heltshe, S.L., Skalland, M., West, N.E., VanDevanter, D.R., Goss, C.H., Flume, P.A.
Published in Journal of cystic fibrosis (01.07.2022)
Published in Journal of cystic fibrosis (01.07.2022)
Get full text
Journal Article
Building global development strategies for cf therapeutics during a transitional cftr modulator era
Mayer-Hamblett, N., van Koningsbruggen-Rietschel, S., Nichols, D.P., VanDevanter, D.R., Davies, J.C., Lee, T., Durmowicz, A.G., Ratjen, F., Konstan, M.W., Pearson, K., Bell, S.C., Clancy, J.P., Taylor-Cousar, J.L., De Boeck, K., Donaldson, S.H., Downey, D.G., Flume, P.A., Drevinek, P., Goss, C.H., Fajac, I., Magaret, A.S., Quon, B.S., Singleton, S.M., VanDalfsen, J.M., Retsch-Bogart, G.Z.
Published in Journal of cystic fibrosis (01.09.2020)
Published in Journal of cystic fibrosis (01.09.2020)
Get full text
Journal Article
A small-molecule nitroimidazopyran drug candidate for the treatment of tuberculosis
Stover, C. Kendall, Warrener, Paul, VanDevanter, Donald R, Sherman, David R, Arain, Taraq M, Langhorne, Michael H, Anderson, Scott W, Towell, J. Andrew, Yuan, Ying, McMurray, David N, Kreiswirth, Barry N, Barry, Clifton E, Baker, William R
Published in Nature (London) (22.06.2000)
Published in Nature (London) (22.06.2000)
Get full text
Journal Article
Detection and analysis of diverse herpesviral species by consensus primer PCR
VANDEVANTER, D. R, WARBENER, P, BENNETT, L, SCHULTZ, E. R, COULTER, S, GARBER, R. L, ROSE, T. M
Published in Journal of Clinical Microbiology (01.07.1996)
Published in Journal of Clinical Microbiology (01.07.1996)
Get full text
Journal Article
Efficacy and safety of ataluren in patients with nonsense-mutation cystic fibrosis not receiving chronic inhaled aminoglycosides: The international, randomized, double-blind, placebo-controlled Ataluren Confirmatory Trial in Cystic Fibrosis (ACT CF)
Konstan, M.W., VanDevanter, D.R., Rowe, S.M., Wilschanski, M., Kerem, E., Sermet-Gaudelus, I., DiMango, E., Melotti, P., McIntosh, J., De Boeck, K.
Published in Journal of cystic fibrosis (01.07.2020)
Published in Journal of cystic fibrosis (01.07.2020)
Get full text
Journal Article
KB001-A, a novel anti-inflammatory, found to be safe and well-tolerated in cystic fibrosis patients infected with Pseudomonas aeruginosa
Jain, Raksha, Beckett, V.V., Konstan, M.W., Accurso, F.J., Burns, J.L., Mayer-Hamblett, N., Milla, Carlos, VanDevanter, D.R., Chmiel, J.F.
Published in Journal of cystic fibrosis (01.07.2018)
Published in Journal of cystic fibrosis (01.07.2018)
Get full text
Journal Article
Design and powering of cystic fibrosis clinical trials using pulmonary exacerbation as an efficacy endpoint
VanDevanter, D.R, Yegin, A, Morgan, W.J, Millar, S.J, Pasta, D.J, Konstan, M.W
Published in Journal of cystic fibrosis (01.12.2011)
Published in Journal of cystic fibrosis (01.12.2011)
Get full text
Journal Article
Microbiological changes observed over 48 weeks of treatment with inhaled liposomal ciprofloxacin in individuals with non-cystic fibrosis bronchiectasis and chronic Pseudomonas aeruginosa lung infection
VanDevanter, D.R., Gonda, I., Dahms, J., Cipolla, D., Davis, A.M., Chalmers, J.D., Froehlich, J.
Published in Clinical microbiology and infection (01.12.2019)
Published in Clinical microbiology and infection (01.12.2019)
Get full text
Journal Article
Heterogeneity of CFTR modulator-induced sweat chloride concentrations in people with cystic fibrosis
Zemanick, E.T., Emerman, I., McCreary, M., Mayer-Hamblett, N., Warden, M.N., Odem-Davis, K., VanDevanter, D.R., Ren, C.L., Young, J., Konstan, M.W.
Published in Journal of cystic fibrosis (01.07.2024)
Published in Journal of cystic fibrosis (01.07.2024)
Get full text
Journal Article
Antipseudomonal treatment decisions during CF exacerbation management
VanDevanter, D.R., West, N.E., Sanders, D.B., Skalland, M., Goss, C.H., Flume, P.A., Heltshe, S.L.
Published in Journal of cystic fibrosis (01.09.2022)
Published in Journal of cystic fibrosis (01.09.2022)
Get full text
Journal Article
Willingness of people with cystic fibrosis receiving elexacaftor/tezacaftor/ivacaftor (ETI) to participate in randomized modulator and inhaled antimicrobial clinical trials
VanDevanter, D.R., Zemanick, E.T., Konstan, M.W., Ren, C.L., Odem-Davis, K., Emerman, I., Young, J., Mayer-Hamblett, N.
Published in Journal of cystic fibrosis (01.07.2023)
Published in Journal of cystic fibrosis (01.07.2023)
Get full text
Journal Article
Probability of IV antibiotic retreatment within thirty days is associated with duration and location of IV antibiotic treatment for pulmonary exacerbation in cystic fibrosis
VanDevanter, D.R, Flume, P.A, Morris, N, Konstan, M.W
Published in Journal of cystic fibrosis (01.11.2016)
Published in Journal of cystic fibrosis (01.11.2016)
Get full text
Journal Article
Rationalizing endpoints for prospective studies of pulmonary exacerbation treatment response in cystic fibrosis
VanDevanter, D.R, Heltshe, S.L, Spahr, J, Beckett, V.V, Daines, C.L, Dasenbrook, E.C, Gibson, R.L, Jain, R, Sanders, D.B, Goss, C.H, Flume, P.A
Published in Journal of cystic fibrosis (01.09.2017)
Published in Journal of cystic fibrosis (01.09.2017)
Get full text
Journal Article